RT Journal Article
T1 Nanoparticle-based immunotherapeutics: from the properties of nanocores to the differential effects of administration routes
A1 Pérez Potti, André
A1 Rodríguez Pérez, Manuel
A1 Pelaz García, Beatriz
A1 Pino González de la Higuera, Pablo Alfonso del
K1 Nanoparticles
K1 Immune system
K1 Vaccine
K1 Cancer
K1 Immunotherapy
K1 Combination therapy
AB The engagement with the immune system is one of the main cornerstones in the development of nanotechnologies for therapy and diagnostics. Recent advances have made possible the tuning of features like size, shape and biomolecular modifications that influence such interactions, however, the capabilities for immune modulation of nanoparticles are still not well defined and exploited. This review focuses on recent advances made in preclinical research for the application of nanoparticles to modulate immune responses, and the main features making them relevant for such applications. We review and discuss newest evidence in the field, which include in vivo experiments with an extensive physicochemical characterization as well as detailed study of the induced immune response. We emphasize the need of incorporating knowledge about immune response development and regulation in the design and application of nanoparticles, including the effect by parameters such as the administration route and the differential interactions with immune subsets
PB Elsevier
SN 0169-409X
YR 2023
FD 2023
LK http://hdl.handle.net/10347/30612
UL http://hdl.handle.net/10347/30612
LA spa
NO Advanced Drug Delivery Reviews 197 (2023) 114829
NO The authors thank the financial support of the European Research Council (starting grant #950421), the European Union (INTERREG V-A Spain–Portugal #0624_2IQBIONEURO_6_E, NextGeneration EU/PRTR and ERDF; H2020-FET-Open grant agreement No. 899612), the MCIN/AEI (PID2020-119206RB-I00, PID2020-119479RA-I00, PID2019-111218RB-I00, RYC-2017-23457, RYC-2019-028238-I and RYC2021‐034576‐I), and the Xunta de Galicia (ED431F 2021/02, 2021-CP090, ED431C 2022/018, and Centro Singular De Investigación de Galicia Accreditation 2019–2022 #ED431G 2019/03). This project was also supported by the ISCIII, under the framework of EuroNanoMed III_2020 (AC20/00041, PLATMED)
DS Minerva
RD 24 abr 2026